Open company graph database — free web & API
Login

JCR Pharma Corporation

JCRファーマ株式会社JCR Pharmaceuticals Co., Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
985
Related companies
10
§01

Basic information

BASIC
Head office
3-19 Kasugacho, Ashiya-shi, Hyogo Prefecture
Chief executive
Hiroyuki Sonoda
Capital
9,061,860,000  (90 100 million)
Employees (non-consolidated)
937 people
Employees (consolidated)
985 people
Start date
1975-09-13
End date
§02

Websites

1 DOMAINS
§03

Business

4
Sale of medical devicesManufacture and sale of medical pharmaceuticalsManufacture and sale of regenerative medicine productsManufacture, procurement, and sale of pharmaceutical raw materials
§04

Related companies

10 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
JCR DO BRASIL PHARMACEUTICALS IMPORTATION AND EXPORTATION LTD.
Group
JCR Europe B.V.
Group
JCR INTERNATIONAL SA
Group
JCR Luxembourg S.A.
Group
JCR USA, Inc.
Group
JCR Engineering Co., Ltd.
Group
Chromatic Co., Ltd.
Group
AlliedCel Inc.
Group
ArmaGen, Inc.
Group
Sumitomo Mitsui Trust Bank, Limited
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

162 EVENTS

Establishment of Japan Chemical Research Co., Ltd.Sources

Founded Nippon Chemical ResearchSources

Established Mikage Factory in Higashinada-ku, Kobe City, Hyogo PrefectureSources

Opened the Mikage Plant in Higashinada-ku, Kobe, HyogoSources

Established a method for refining urokinase (thrombolytic agent) raw materialSources

Established a purification method for urokinase drug substance, a thrombolytic agentSources

Set up a research institute within Mikage FactorySources

Opened a research laboratory at the Mikage PlantSources

Relocated the research institute to Chuo-ku, Kobe City, Hyogo PrefectureSources

Relocated the research laboratory to Chuo-ku, Kobe, HyogoSources

Obtained manufacturing approval for urokinase preparations and raw solutionsSources

Received manufacturing approval for urokinase drug product and bulk solutionSources

Obtained import approval for human growth hormone preparation "Growlum"Sources

Received import approval for Growlum, a human growth hormone productSources

Opened Tokyo Office in Shibuya-ku, TokyoSources

Opened the Tokyo Office in Shibuya-ku, TokyoSources

Established Nishishin Factory in Nishishin Industrial Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Seishin Plant in Nishi-ku, Kobe, Hyogo (Seishin Industrial Park)Sources

Relocated the research institute adjacent to Nishishin FactorySources

Relocated the research laboratory to a site adjacent to the Seishin PlantSources

Registered as a over-the-counter listed stock with the Japan Securities Dealers AssociationSources

Registered as an over-the-counter stock with the Japan Securities Dealers AssociationSources

Obtained manufacturing approval for genetically engineered human growth hormone preparation "Growject® 4IU"Sources

Received manufacturing approval for GROWJECT™ Injection 4IU, a recombinant human growth hormone productSources

Relocated headquarters to current location at Kasugacho, Ashiya City, Hyogo PrefectureSources

Relocated headquarters to Kasuga-cho, Ashiya, Hyogo (current location)Sources

Launched "TwinJector® EZ" pressure injector without needle for "Growject®"Sources

Launched TWINJECTOR® EZ, a needle-free pressure injector for GROWJECT™Sources

Constructed and relocated research institute to Kobe High-Tech Park in Nishi-ku, Kobe City, Hyogo PrefectureSources

Relocated the research laboratory to Nishi-ku, Kobe, Hyogo (Kobe High-Tech Park)Sources

Obtained manufacturing approval for urinastatin raw solution "JCR"Sources

Received manufacturing approval for Ulinastatin Bulk Solution “JCR,” a protease inhibitor drug substanceSources

Approval for manufacturing of Urinastatin raw material "JCR" (protein-degrading enzyme inhibitor raw material)Sources

Established the Nish-Shin-Minami Factory in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Seishin South Plant in Kobe High-Tech ParkSources

Listed on the Osaka Securities Exchange Second SectionSources

Listed on the Second Section of the Osaka Securities ExchangeSources

Established 'JCR Biopharmaceuticals, Inc.' in the United StatesSources

Established JCR Biopharmaceuticals, Inc. in the United StatesSources

Established a joint venture 'Jiexi Pharmaceutical Co., Ltd.' with Beijing Shanhai Pharmaceutical and Health Development Co., Ltd. in ChinaSources

Established Jiexi Pharmaceutical Co., Ltd. in China through a joint venture with Beijing Shanhe Medical & Health Development Co., Ltd., wholly owned by Beijing HospitalSources

Established a joint venture "Jiexi Pharmaceutical Co., Ltd." with Beijing Shanhai Medical and Health Development Co., Ltd. (100% owned by Beijing Hospital, China)Sources

Started import and sales of injection accessories 'Conijector® Pen' for 'Glowject®'Sources

Began importing and marketing the KONYJECTOR® Pen, an injection aid for GROWJECT™Sources

Established a medical device sales company 'Family Health Rental Co., Ltd.' in Chuo-ku, Kobe City, Hyogo PrefectureSources

Established Family Health Rental Co., Ltd., a medical device sales company, in Chuo-ku, Kobe, HyogoSources

Initiated sales partnership with Sumitomo Pharmaceutical Co., Ltd. for recombinant human growth hormone formulation 'Glowject® Injections 4IU'Sources

Entered into a marketing alliance with Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for GROWJECT™ Injection 4IUSources

Started sales partnership with Sumitomo Pharmaceutical Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for recombinant human growth hormone preparation "Growject® 4IU"Sources

Succeeded to the manufacturing approval of leukopenia treatment 'Leukoprorol®' from Morinaga Milk Industry Co., Ltd.Sources

Assumed manufacturing approval for Leukoprol®, a treatment for leukopenia, from Morinaga Milk Industry Co., Ltd.Sources

Obtained manufacturing approval for 'Glowject® Injections 24IU' and 'Glowject® BC24'Sources

Received manufacturing approval for GROWJECT™ Injection 24IU and GROWJECT™ BC24Sources

Obtained additional indication approval for 'Glowject® Injections 4IU' for 'short stature due to Turner syndrome without epiphyseal closure'Sources

Received approval for an additional indication for GROWJECT™ Injection 4IU for short stature in Turner syndrome without closed epiphysesSources

Established Kobe Factory in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Kobe Plant in Kobe High-Tech ParkSources

Launched recombinant human growth hormone formulations 'Glowject® Injections 1.33mg', 'Glowject® Injections 8mg', 'Glowject® BC8mg' and pen-type injector 'Glowject® Pen'Sources

Launched GROWJECT™ Injection 1.33mg, GROWJECT™ Injection 8mg, GROWJECT™ BC8mg, and the GROWJECT™ Pen injectorSources

Established 'Chromatec Co., Ltd.' in Nishinomiya City, Hyogo Prefecture for research and medical device salesSources

Established Chromatec Co., Ltd., a distributor of research and medical equipment, in Nishinomiya, HyogoSources

Launched 'Glowject® Pen 0.1mg', a pen-type injector with mg increments to accommodate formulation unit changesSources

Launched GROWJECT™ Pen 0.1mg, a pen injector with 0.1 mg increments reflecting revised product specificationsSources

Launched 'TwinJector® EZ II', a needleless pressure injector for 'Glowject®'Sources

Launched TWINJECTOR® EZ II, a needle-free pressure injector for GROWJECT™Sources

Established a clinical trial drug manufacturing center (currently Moritani Factory) in Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Clinical Trial Product Manufacturing Center (now Murotani Plant) in Kobe High-Tech ParkSources

Launched an improved version of 'Glowject® Pen', a dedicated injector for 'Glowject®', called 'BD PenJector™ 2'Sources

Launched the BD PenJector™ 2, an improved injector for GROWJECT™Sources

Started sales of imported raw materials of anticancer agent 'Paclitaxel' to Nippon Kayaku Co., Ltd.Sources

Began marketing imported paclitaxel drug substance, an anticancer agent, to Nippon Kayaku Co., Ltd.Sources

Launched 'Glowject®', an electric injection device dedicated to 'Glowject®'Sources

Launched the GROWJECTER®, an electric injector for GROWJECT™Sources

Established Moritani Factory in Nishi-ku, Kobe City, Hyogo Prefecture (reorganized from clinical trial drug manufacturing center)Sources

Opened the Murotani Plant in Kobe High-Tech Park, reorganized from the Clinical Trial Product Manufacturing CenterSources

Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "Adult Growth Hormone Deficiency"Sources

Established Kobe West Factory as a manufacturing plant for human mesenchymal stem cells in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Received approval for an additional indication for GROWJECT™ for adult growth hormone deficiencySources

Opened the Kobe Nishi Plant in Kobe High-Tech Park as a manufacturing facility for human mesenchymal stem cellsSources

Launched "BD Penjector™3", the successor to the dedicated injector for "Growject®" "BD Penjector™2"Sources

Launched the BD PenJector™ 3, the successor to the BD PenJector™ 2 injector for GROWJECT™Sources

Launched the renal anemia treatment drug "Epoetin Alpha BS Injection "JCR""Sources

Launched Epoetin Alfa BS Injection “JCR,” Japan’s first biosimilar for the treatment of renal anemiaSources

Launched the first domestically produced biopharmaceutical for renal anemia, "Epoetin Alpha BS" (JCR)Sources

Listed on the Second Section of the Tokyo Stock ExchangeSources

Listed on the Second Section of the Tokyo Stock ExchangeSources

Established "JCR Engineering Inc." in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture, to manage pharmaceutical manufacturing equipment, facilities, and machinerySources

Established JCR Engineering Co., Ltd. in Kobe High-Tech Park to manage pharmaceutical manufacturing facilities, equipment, and instrumentsSources

Launched "Glowject®" dedicated electric injector "Glowject®"Sources

Launched GROWJECTER® 2, the successor to the GROWJECTER® electric injector for GROWJECT™Sources

Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "SGA short stature without epiphyseal closure"Sources

JCR receives an Approval for Expanded Indication of Growject™ in Short Stature due to Small-for-Gestational Age (SGA)Sources

JCR receives an approval for expanded indication of Growject™ in short stature due to Small-for-Gestational Age (SGA)Sources

Established Kobe Active Pharmaceutical Ingredient Plant in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Kobe API Plant in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park)Sources

Listed on the First Section of the Tokyo Stock ExchangeSources

Listed on the First Section of the Tokyo Stock ExchangeSources

Changed company name to JCR Pharma Co., Ltd.Sources

Renamed to JCR Pharmaceuticals Co., Ltd.Sources

Established Kobe Logistics Center in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Kobe Logistics Center in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park)Sources

Established market research company "JCR INTERNATIONAL SA" in SwitzerlandSources

Established JCR INTERNATIONAL SA, a market research company, in SwitzerlandSources

Launched Japan's first allogeneic regenerative medicine product "Temcell®HS Injection"Sources

Launched TEMCELL™ HS Inj., Japan’s first allogeneic regenerative medicine product.Sources

Established clinical trial drug manufacturing center and cell processing center within the research institute siteSources

Opened a Clinical Trial Drug Manufacturing Center and a Cell Processing Center within the research institute premisesSources

Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product “Growject™Sources

Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product "Growject™"Sources

Obtained approval for manufacturing and sales of liquid formulation of "Growject®"Sources

Launched "Glowject®" liquid formulation dedicated electric injector "Glowject®L"Sources

Launched “Growjecter® L,” an electric injection device dedicated to the liquid formulation of “Growject™Sources

Launched "Growjecter® L," an electric injection device dedicated to the liquid formulation of "Growject™"Sources

Established JCR USA, Inc., a global management company for clinical development in the United StatesSources

Established JCR USA, Inc. in the United States to oversee clinical developmentSources

Launched "Argalactosidase Beta BS Intravenous Infusion "JCR"", the company's first lysosomal storage disease enzyme preparationSources

Launched Agalsidase Beta BS Intravenous Infusion “JCR,” the Company’s first enzyme replacement therapy for lysosomal storage disordersSources

Launched the long-acting erythropoiesis-stimulating agent “Darbepoetin Alfa BS Injection ‘JCR’Sources

Launched the long-acting erythropoiesis-stimulating agent "Darbepoetin Alpha BS" (JCR)Sources

Launched the long-acting erythropoiesis-stimulating agent "Darbepoetin Alfa BS Injection ‘JCR"Sources

Acquired all shares of US pharmaceutical research and development company "ArmaGen, Inc."Sources

Merged with Family Health Rental CorporationSources

Acquired all shares of ArmaGen, Inc., a U.S. biopharmaceutical R&D companySources

Absorbed and merged Family Health Rental Co., Ltd.Sources

The company "JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA." which conducts clinical operations, pharmaceutical affairs, and development activities within the Federative Republic of Brazil has commenced business activitiesSources

JCR DO BRASIL PHARMACEUTICALS IMPORTATION AND EXPORTATION LTD. started operationsSources

Co-developed a smartphone application software "Melon Diary®" for the dedicated injector "Growject®L" of "Growject®" in collaboration with PHC CorporationSources

Co-developed Meron Diary®, a smartphone app for the GROWJECTER® L injector for GROWJECT™, with PHC CorporationSources

Signed a contract with AstraZeneca K.K. for manufacturing the domestic raw liquid of the new coronavirus vaccine "AZD1222"Sources

Entered into a manufacturing services agreement with AstraZeneca K.K. for domestic drug substance production of the COVID-19 vaccine AZD1222Sources

Established a bio-research center in Nishi-ku, Kobe City, Hyogo Prefecture (Kobe High-Tech Park)Sources

Opened the Bioresearch Center in Kobe High-Tech ParkSources

Launched the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion 10mg" in JapanSources

Launched IZCARGO™ for I.V. Infusion 10mg in JapanSources

At "WORLDSymposium™ 2022," the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion" received the New Treatment AwardSources

IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLDSymposium™ 2022Sources

IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLD : Symposium : ™ 2022Sources

Reclassified from the First Section of the Tokyo Stock Exchange to the Prime Market due to a review of market segmentsSources

Transferred the sales of "Agalsidase Beta BS Intravenous Infusion 'JCR'" to Sumitomo Pharma Co., Ltd.Sources

Moved from the First Section to the Prime Market of the Tokyo Stock Exchange following the market restructuringSources

Transferred marketing of Agalsidase Beta BS Intravenous Infusion “JCR” to Sumitomo Pharma Co., Ltd.Sources

Established "JCR Luxembourg S.A." in the Grand Duchy of LuxembourgSources

Established JCR Luxembourg S.A. as a European base for global distribution managementSources

Established "JCR Luxembourg S.A." as the European base for global distribution management of Luxembourg Grand DuchySources

Established "JCR Europe B.V." in the Kingdom of the Netherlands, a company overseeing clinical developmentSources

Established JCR Europe B.V. in the Netherlands to oversee clinical developmentSources

Selected for the Ministry of Economy, Trade and Industry’s program to strengthen biopharmaceutical manufacturing infrastructure for vaccine productionSources

Established "AlliedCel Inc." in Chuo-ku, Kobe City, Hyogo Prefecture, jointly with Sysmex Corporation, to conduct research and development of regenerative medicine productsSources

Acquired shares of the Taiwanese biopharmaceutical manufacturing and development contract company "Mycenax Biotech Inc."Sources

Established AlliedCel Corporation with Sysmex Corporation to conduct R&D on regenerative medicine productsSources

Acquired shares of Mycenax Biotech Inc., a Taiwanese biopharmaceutical CDMOSources

Established Kobe Science Park Center in Nishi-ku, Kobe City, Hyogo PrefectureSources

Opened the Kobe Science Park Center in Kobe Science ParkSources

Obtained approval for the additional efficacy of the genetically engineered human growth hormone "Growject®" for "short stature with SHOX deficiency without epiphyseal closure"Sources

Received approval for an additional indication for GROWJECT™ for short stature associated with SHOX deficiency without closed epiphysesSources

Launched a new electric injector "Growject® Duo" jointly developed with PHC Corporation for "Growject®"Sources

Launched GROWJECTER® Duo, a new electric injector for GROWJECT™, co-developed with PHC CorporationSources

Revised corporate philosophy and core valuesSources

Revised the corporate philosophy and core valuesSources

Revised the corporate philosophy and core values : 9 : Adopted the corporate slogan “Life is Rare”Sources

Established the corporate slogan "Life is Rare"Sources

Adopted the corporate slogan “Life is Rare”Sources

§07

News

6 ARTICLES

PHP Vulnerability Response NoticeSources

JCR Pharmaceuticals has temporarily suspended certain services on its websites in response to a PHP vulnerability. No incidents, including data leaks, have been identified. Services will resume once necessary security measures are implemented and safety is confirmed.

Response to PHP VulnerabilitiesSources

As a preventive measure against PHP vulnerabilities, the login functions of "Growth Hormone Pro" and "Mucopolysaccharidosis Pro" have been suspended since October 22, 2026. At present, no information leakage or other incidents have been confirmed, and the services are scheduled to resume after safety verification is completed. The corporate website and the same site (GLOBAL) have already been addressed.

Publication of a Shared Research ReportSources

A research report on JCR Pharmaceuticals has been published by Shared Research Inc. The report can be viewed via the provided link.

JCR Pharma releases IR seminar videoSources

We released a recording of the investor IR seminar "Bridge Salon" held on September 12, 2026. The video explains the company's business and growth strategy and answers questions from investors. The distribution period is until March 29, 2027.

JCR Pharmaceuticals to Speak at Bridge Salon Investor SeminarSources

JCR Pharmaceuticals Co., Ltd. will speak at Bridge Salon, an investor relations seminar for individual investors, on September 12, 2026. The company will explain its business and growth strategy. The event will be held in a hybrid format, with in-person and online participation. Advance registration is required, and the livestream will be free to watch.

JCR Pharma, Partial Correction of Shareholders' Meeting NoticeSources

JCR Pharma announced that it had corrected errors in the notice of the 51st regular shareholders' meeting.

§08

Public records

GOV
National Tax Agency basic information6140001000905
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
JCRファーマ株式会社
Trade name (kana)
ジェーシーアールファーマ
Name in English
Corporation type
301
Address
〒659-0021 兵庫県芦屋市春日町3番19号
Postal code
6590021
Prefecture code
28
City code
206
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-04-17
Change date
2020-04-06
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和2年4月1日神戸市西区室谷一丁目2番3号株式会社ファミリーヘルスレンタル(7140001010523)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
0
Trade name image ID
Address image ID
Sequence number
4575236
METI gBizINFO6140001000905
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6140001000905
Trade name
JCRファーマ株式会社
Trade name (kana)
ジェーシーアールファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
兵庫県芦屋市春日町3番19号
Postal code
6590021
Prefecture
兵庫県
Prefecture code
28
City or district
芦屋市
City code
206
Street address
春日町3番19号
Organisation type
301
Processing type
71
Correction type
0
Status
Representative
代表取締役社長  薗田 啓之
Capital
9061000000
Employees
938
Employees (male)
546
Employees (female)
391
Business summary
医薬品、再生医療等製品およびその原料の製造、売買ならびに輸出入医療用機器および実験用機器の売買ならびに輸出入
Website URL
http://www.jcrpharm.co.jp/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2020-04-17
Key information
6140001000905
§09

Sources & updates

SOURCES
↑